Precision medicine in pediatric oncology

Stefan E.G. Burdach; Mike Andrew Westhoff; Maximilian Felix Steinhauser; Klaus Michael Debatin

doi:10.1186/s40348-018-0084-3

Precision medicine in pediatric oncology

Stefan E.G. Burdach, Mike Andrew Westhoff, Maximilian Felix Steinhauser, Klaus Michael Debatin

Medicine and Health

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Abstract

Outcome in treatment of childhood cancers has improved dramatically since the 1970s. This success was largely achieved by the implementation of cooperative clinical research trial groups that standardized and developed treatment of childhood cancer. Nevertheless, outcome in certain types of malignancies is still unfavorable. Intensification of conventional chemotherapy and radiotherapy improved outcome only marginally at the cost of acute and long-term side effects. Hence, it is necessary to develop targeted therapy strategies. Here, we review the developments and perspectives in precision medicine in pediatric oncology with a special focus on targeted drug therapies like kinase inhibitors and inducers of apoptosis, the impact of cancer genome sequencing and immunotherapy.

Original language	English
Article number	6
Journal	Molecular and Cellular Pediatrics
Volume	5
Issue number	1
DOIs	https://doi.org/10.1186/s40348-018-0084-3
State	Published - 1 Dec 2018

Keywords

Childhood cancer
Immunotherapy
T-cell-based therapy
Targeted drug therapies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40348-018-0084-3

Cite this

@article{3383a9d008d3487eba60a85d16679378,

title = "Precision medicine in pediatric oncology",

abstract = "Outcome in treatment of childhood cancers has improved dramatically since the 1970s. This success was largely achieved by the implementation of cooperative clinical research trial groups that standardized and developed treatment of childhood cancer. Nevertheless, outcome in certain types of malignancies is still unfavorable. Intensification of conventional chemotherapy and radiotherapy improved outcome only marginally at the cost of acute and long-term side effects. Hence, it is necessary to develop targeted therapy strategies. Here, we review the developments and perspectives in precision medicine in pediatric oncology with a special focus on targeted drug therapies like kinase inhibitors and inducers of apoptosis, the impact of cancer genome sequencing and immunotherapy.",

keywords = "Childhood cancer, Immunotherapy, T-cell-based therapy, Targeted drug therapies",

author = "Burdach, {Stefan E.G.} and Westhoff, {Mike Andrew} and Steinhauser, {Maximilian Felix} and Debatin, {Klaus Michael}",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1186/s40348-018-0084-3",

language = "English",

volume = "5",

journal = "Molecular and Cellular Pediatrics",

issn = "2194-7791",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Precision medicine in pediatric oncology

AU - Burdach, Stefan E.G.

AU - Westhoff, Mike Andrew

AU - Steinhauser, Maximilian Felix

AU - Debatin, Klaus Michael

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Outcome in treatment of childhood cancers has improved dramatically since the 1970s. This success was largely achieved by the implementation of cooperative clinical research trial groups that standardized and developed treatment of childhood cancer. Nevertheless, outcome in certain types of malignancies is still unfavorable. Intensification of conventional chemotherapy and radiotherapy improved outcome only marginally at the cost of acute and long-term side effects. Hence, it is necessary to develop targeted therapy strategies. Here, we review the developments and perspectives in precision medicine in pediatric oncology with a special focus on targeted drug therapies like kinase inhibitors and inducers of apoptosis, the impact of cancer genome sequencing and immunotherapy.

AB - Outcome in treatment of childhood cancers has improved dramatically since the 1970s. This success was largely achieved by the implementation of cooperative clinical research trial groups that standardized and developed treatment of childhood cancer. Nevertheless, outcome in certain types of malignancies is still unfavorable. Intensification of conventional chemotherapy and radiotherapy improved outcome only marginally at the cost of acute and long-term side effects. Hence, it is necessary to develop targeted therapy strategies. Here, we review the developments and perspectives in precision medicine in pediatric oncology with a special focus on targeted drug therapies like kinase inhibitors and inducers of apoptosis, the impact of cancer genome sequencing and immunotherapy.

KW - Childhood cancer

KW - Immunotherapy

KW - T-cell-based therapy

KW - Targeted drug therapies

UR - http://www.scopus.com/inward/record.url?scp=85063292378&partnerID=8YFLogxK

U2 - 10.1186/s40348-018-0084-3

DO - 10.1186/s40348-018-0084-3

M3 - Review article

AN - SCOPUS:85063292378

SN - 2194-7791

VL - 5

JO - Molecular and Cellular Pediatrics

JF - Molecular and Cellular Pediatrics

IS - 1

M1 - 6

ER -

Precision medicine in pediatric oncology

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this